ICVX
Closed
Icosavax Inc
15.31
0.00 (0.00%)
Last Update: 29 Feb 2024 17:30:00
Yesterday: 15.31
Day's Range: 15.31 - 15.31
Send
sign up or login to leave a comment!
When Written:
6.395
Icosavax Inc is a clinical-stage biotechnology company that specializes in developing vaccines and immunotherapies to prevent and treat infectious diseases. The company was founded in 2017 and is headquartered in Seattle, Washington.
Icosavax's lead product candidate is a vaccine for respiratory syncytial virus (RSV), a common virus that can cause severe respiratory illness, particularly in infants and the elderly. The vaccine is designed to stimulate the immune system to produce antibodies that can neutralize the virus and prevent infection.
In addition to RSV, Icosavax is also developing vaccines for other infectious diseases, including COVID-19, human metapneumovirus, and parainfluenza virus. The company's vaccines use a proprietary virus-like particle (VLP) technology that mimics the structure of the virus but does not contain the genetic material that causes disease.
Icosavax has raised over $200 million in funding from investors, including the Bill and Melinda Gates Foundation, Qiming Venture Partners, and Adjuvant Capital. The company has also partnered with several pharmaceutical companies, including Serum Institute of India, to develop and manufacture its vaccines.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Icosavax's lead product candidate is a vaccine for respiratory syncytial virus (RSV), a common virus that can cause severe respiratory illness, particularly in infants and the elderly. The vaccine is designed to stimulate the immune system to produce antibodies that can neutralize the virus and prevent infection.
In addition to RSV, Icosavax is also developing vaccines for other infectious diseases, including COVID-19, human metapneumovirus, and parainfluenza virus. The company's vaccines use a proprietary virus-like particle (VLP) technology that mimics the structure of the virus but does not contain the genetic material that causes disease.
Icosavax has raised over $200 million in funding from investors, including the Bill and Melinda Gates Foundation, Qiming Venture Partners, and Adjuvant Capital. The company has also partnered with several pharmaceutical companies, including Serum Institute of India, to develop and manufacture its vaccines.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!